Patient wellbeing study for ALK-positive advanced lung cancer in China
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well ALK-positive advanced lung cancer patients feel during normal treatment with ALK inhibitors. Researchers want to learn about your symptoms and quality of life so they can improve care for other patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and willing to sign a consent form.
- Your lung cancer must be ALK-positive, meaning a special protein change was found on a test.
- Your doctor has prescribed or will prescribe an ALK inhibitor (a daily pill) as your first or later treatment.
- You should be able to follow the study schedule and have a life expectancy of at least 12 weeks.
- Your cancer may have spread to your brain as long as you have no symptoms from it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This study looks at why some lung cancers with an ALK gene change do not respond to ALK-targeted drugs. It may help find better treatments for patients whose cancer stops responding early.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.